Company / Working Capital
Dianthus Therapeutics, Inc. /DE/ Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$378.7M
FY2025
5-year range
$73.8M / $378.7M
FY2021-FY2025
Trend
+44.3%
vs FY2024
Sector context
#116 of 213
Health Care
What the data says
At $379M, Dianthus Therapeutics, Inc. /DE/'s working capital ranks #116 of 213 in the Health Care sector. Working Capital has increased for 3 consecutive years, from $74M in FY2022 to $379M in FY2025.
Based on SEC 10-K filings.
$379M in FY2025 with a 5-year CAGR of +22.0%.
Improved from $168M to $379M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +72.5%
- 5-Year CAGR
- +22.0%
- 10-Year CAGR
- -
Sector benchmark
#116 of 213 in Health CareTop 54% of 213This company $378.7M Sector average $934.6M
▼
-59.5% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +22.0%, indicating consistent growth.
- In FY2025, working capital increased 44.3% year-over-year.
- Ranks #116 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $378.7M | +44.3% |
| FY2024 | $262.5M | +56.4% |
| FY2023 | $167.8M | +127.4% |
| FY2022 | $73.8M | -56.5% |
| FY2021 | $169.8M | +21.2% |
| FY2020 | $140.1M | +3.2% |
| FY2019 | $135.7M | +0.6% |
| FY2018 | $134.9M | +178.9% |
| FY2017 | $48.4M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026